BACKGROUND: Little is known about the extent of heterogeneity of symptomatology in treated early-onset psychosis. The current study aims to quantify the extent of heterogeneity in trajectories of treated symptom severity in early-episode psychosis and their antecedents. METHODS: Data were from 491 persons with early-episode psychosis from a clinical trial ofhaloperidol and risperidone. Positive and Negative Syndrome Scale (PANSS) administrations were used to measure symptom severity trajectories for (a) rapid treatment response scores over 4 weeks and (b) medium-term course over 24 weeks. Baseline antecedents included sex, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, diagnosis, age of onset, the Premorbid Adjustment Scale, and a cognitive test battery. Symptom severity trajectories were calculated with mixed mode latent class regression modeling from which groups were derived. RESULTS: Five groups based on PANSS scores over time were identified. Over 4 weeks, 3 groups with varied baseline PANSS scores (54-105) did not surpass 30% PANSS improvement. Another group improved and then was stable (n = 76,15.3%), and another showed marked improvement (n = 94,18.9%). Logistic regression showed that membership in the best response trajectory was associated with not having a diagnosis of schizophrenia, good premorbid functioning, and higher cognitive functioning, whereas membership in the poor response trajectory was associated with earlier age of onset and poorer cognitive functioning. CONCLUSION: Amelioration generally characterizes treated symptom severity. Age of onset, diagnosis, cognitive functioning, and premorbid functioning have prognostic value in predicting treatment response trajectories.
RCT Entities:
BACKGROUND: Little is known about the extent of heterogeneity of symptomatology in treated early-onset psychosis. The current study aims to quantify the extent of heterogeneity in trajectories of treated symptom severity in early-episode psychosis and their antecedents. METHODS: Data were from 491 persons with early-episode psychosis from a clinical trial of haloperidol and risperidone. Positive and Negative Syndrome Scale (PANSS) administrations were used to measure symptom severity trajectories for (a) rapid treatment response scores over 4 weeks and (b) medium-term course over 24 weeks. Baseline antecedents included sex, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, diagnosis, age of onset, the Premorbid Adjustment Scale, and a cognitive test battery. Symptom severity trajectories were calculated with mixed mode latent class regression modeling from which groups were derived. RESULTS: Five groups based on PANSS scores over time were identified. Over 4 weeks, 3 groups with varied baseline PANSS scores (54-105) did not surpass 30% PANSS improvement. Another group improved and then was stable (n = 76,15.3%), and another showed marked improvement (n = 94,18.9%). Logistic regression showed that membership in the best response trajectory was associated with not having a diagnosis of schizophrenia, good premorbid functioning, and higher cognitive functioning, whereas membership in the poor response trajectory was associated with earlier age of onset and poorer cognitive functioning. CONCLUSION: Amelioration generally characterizes treated symptom severity. Age of onset, diagnosis, cognitive functioning, and premorbid functioning have prognostic value in predicting treatment response trajectories.
Authors: Edward D Barker; Jean R Séguin; Helene Raskin White; Marsha E Bates; Eric Lacourse; René Carbonneau; Richard E Tremblay Journal: Arch Gen Psychiatry Date: 2007-05
Authors: Abraham Reichenberg; Philip D Harvey; Christopher R Bowie; Ramin Mojtabai; Jonathan Rabinowitz; Robert K Heaton; Evelyn Bromet Journal: Schizophr Bull Date: 2008-05-20 Impact factor: 9.306
Authors: Candice L Odgers; Avshalom Caspi; Jonathan M Broadbent; Nigel Dickson; Robert J Hancox; Honalee Harrington; Richie Poulton; Malcolm R Sears; W Murray Thomson; Terrie E Moffitt Journal: Arch Gen Psychiatry Date: 2007-04
Authors: Rebecca Schennach; Hans-Jürgen Möller; Michael Obermeier; Florian Seemüller; Markus Jäger; Max Schmauss; Gerd Laux; Herbert Pfeiffer; Dieter Naber; Lutz G Schmidt; Wolfgang Gaebel; Joachim Klosterkötter; Isabella Heuser; Wolfgang Maier; Matthias R Lemke; Eckart Rüther; Stefan Klingberg; Markus Gastpar; Richard Musil; Ilja Spellmann; Michael Riedel Journal: Int J Methods Psychiatr Res Date: 2015-07-14 Impact factor: 4.035
Authors: Gary Remington; Donald Addington; William Honer; Zahinoor Ismail; Thomas Raedler; Michael Teehan Journal: Can J Psychiatry Date: 2017-07-13 Impact factor: 4.356
Authors: William G Honer; Andrea A Jones; Allen E Thornton; Alasdair M Barr; Ric M Procyshyn; Fidel Vila-Rodriguez Journal: Can J Psychiatry Date: 2015-03 Impact factor: 4.356
Authors: Linus Jönsson; Jacob Simonsen; Cecilia Brain; Steven Kymes; Louise Watson Journal: Int J Methods Psychiatr Res Date: 2019-04-07 Impact factor: 4.035
Authors: Nicolas A Crossley; Tiago Reis Marques; Heather Taylor; Chris Chaddock; Flavio Dell'Acqua; Antje A T S Reinders; Valeria Mondelli; Marta DiForti; Andrew Simmons; Anthony S David; Shitij Kapur; Carmine M Pariante; Robin M Murray; Paola Dazzan Journal: Brain Date: 2016-12-21 Impact factor: 13.501
Authors: M Case; V L Stauffer; H Ascher-Svanum; R Conley; S Kapur; J M Kane; S Kollack-Walker; J Jacob; B J Kinon Journal: Psychol Med Date: 2010-10-07 Impact factor: 7.723